Bio-rad Laboratories, Inc. · NYSE:BIO

Bio-rad Laboratories — Q3 2025 Earnings Presentation

17 slides from Bio-rad Laboratories's earnings presentation, Oct 29, 2025

  1. Slide 1: Bio-Rad Laboratories, Inc. Third Quarter 2025 Financial Results

    Bio-Rad Laboratories, Inc. Third Quarter 2025 Financial Results October 29, 2025

  2. Slide 2: Safe Harbor

    Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding managementʼs goals, plans, and expectations, our future financial performance, our future

  3. Slide 3: Q3 2025 GAAP Financial Results

    Q3 2025 GAAP Financial Results NET CASH REVENUE GROSS MARGIN OPERATING MARGIN FROM OPERATIONS $653M 52.6% 10.0% $121M 0.5% YoY 220bps YoY 10bps YoY $43M YoY -1.7% YoY CN* * Currency Neutral Revenue: we report percentage sales growth in currency neutral amounts by calculating translated prior peri

  4. Slide 4: Q3 2025 Non-GAAP Financial Results

    Q3 2025 Non-GAAP* Financial Results NONGAAP NONGAAP FREE REVENUE GROSS MARGIN* OPERATING MARGIN* CASH FLOW * $653M 53.5% 11.8% $89M 0.5% YoY 210bps YoY 50bps YoY $34M YoY -1.7% YoY CN** * Reconciliations to the comparable GAAP measure for the non-GAAP items shown above are detailed in the recon

  5. Slide 5: Q3 2025 Business Segment Revenue & Geographic Mix

    Q3 2025 Business Segment Revenue & Geographic Mix Revenue by Business Segment Revenue by Region APAC 19% Americas Clinical Life 47% Diagnostics Science 60% $653M 40% $653M EMEA 34% 5

  6. Slide 6: Life Science Group Q3 2025 Revenue

    Life Science Group Q3 2025 REVENUE Geographic Revenue Mix $262M APAC 18% 0.3% YoY Americas $262M 52% 1.5% YoY CN* EMEA 30% • Segment CN* results impacted by constrained academic research and Product Revenue Mix biotech funding • CN* revenue decline in the Americas Process Chrom Life Science Strong

  7. Slide 7: Clinical Diagnostics Group Q3 2025 Revenue

    Clinical Diagnostics Group Q3 2025 REVENUE $391M Geographic Revenue Mix 0.6% YoY APAC 1.8% YoY CN* 19% Americas 44% • Segment CN* results primarily impacted by lower reimbursement rates for $391M diabetes testing in China • CN* revenue decline in Asia Pacific partially offset by increased sales in

  8. Slide 8: Balance Sheet Highlights

    Balance Sheet Highlights In $ millions) September 30, 2025 December 31, 2024 Cash & Short-Term Investments $1,419 * $1,665 Long-Term Debt $1,201 $1,200 Inventories, net $783 $760 Investment in Sartorius AG $4,643 $4,469 * Cash balance change due to share repurchases, and the completion of Stilla Te

  9. Slide 9: Maintaining Full-Year 2025 Outlook

    Maintaining Full-Year 2025 Outlook Revenue CN* YoY 0.0% to 1.0% Life Science Revenue CN* YoY 0.0% to 1.0% Clinical Diagnostics Revenue CN* YoY 0.5% to 1.5% Non-GAAP Gross Margin** 53.5% to 54.5% Non-GAAP Operating Margin ** 12.0% to 13.0% Free Cash Flow ** $310M to $330M * Currency Neutral Reven

  10. Slide 10: Appendix

    BIO-RAD Appendix

  11. Slide 11: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures This presentation includes GAAP financial measures as well as non-GAAP financial measures, which are not meant to be considered in isolation or as a substitute for comparable GAAP measures. We present certain non-GAAP financial measures to evaluate business perform

  12. Slide 12: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

    Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

  13. Slide 13: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)

    Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)

  14. Slide 14: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)

    Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)

  15. Slide 15: Explanations of Non-GAAP Adjustments

    Explanations of Non-GAAP Adjustments Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of amortization can vary significantly and are unique to each acquisit

  16. Slide 16: Other Key Metrics

    Other Key Metrics Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operationsʼ ability to generate cash for acquisitions and other investing and financing activities. The company also uses this measure as a

  17. Slide 17: 2025 Financial Outlook

    2025 Financial Outlook Forecasted non-GAAP operating margin excludes 103 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, ef

Bio-Rad Laboratories — Q3 2025 Earnings Presentation on 6ix